Skip to main content

Table 2 Rectal adenocarcinomas: observed survival rates calculated by the actuarialmethod (95% confidence interval) by stage (TNM/UICC, 1997) [3] without distinctionof the R-status (R0, R1, R2, Rx) n = 641 cases

From: Rectal cancer in Luxembourg : a national population-based data report, 1988–1998

  Stage I-IV Stage I* Stage II* Stage III* Stage IV*
  n = 641 (100%)   n = 116 (18.1%)   n = 179 (27.9%)   n = 270 (42.1%)   n = 76 (11.9%)  
1 year 78+/-3% (n = 503) 94+/-4% (n = 109) 88+/-5% (n = 157) 70+/-5% (n = 188) 64+/-11% (n = 49)
2 years 64+/-4% (n = 408) 90+/-6% (n = 104) 77+/-6% (n = 137) 50+/-6% (n = 135) 42% ** (n = 32)
3 years 54+/-4% (n = 346) 86+/-6% (n = 100) 65+/-7% (n = 117) 39+/-6% (n = 106) 30% ** (n = 23)
4 years 49+/-4% (n = 315) 86+/-6% (n = 100) 58+/-7% (n = 104) 36+/-6% (n = 97) 18% ** (n = 14)
5 years 46+/-4% (n = 292) 81+/-7% (n = 94) 55+/-7% (n = 98) 34+/-6% (n = 92) 11% ** (n = 8)
  1. * only surgical specimens (n = 641 cases) with available survival data ** standard error omitted sample being too small